Classifying Acute Leukemia by Immunophenotyping: A Combined FAB-Immunologic Classification of AML


A panel of commercially available monoclonal antibodies and five heteroantisera were used to distinguish and subtype 138 cases of acute leukemia (AL). The immunophenotype was compared with the French-American-British (FAB) classification obtained on the cases. The immunophenotype discriminated acute myelogenous leukemia (AML) from acute lymphoblastic leukemia (ALL) and recognized cases not distinguished by cytochemistry (22% of cases), mixed lineage phenotypes (13% of cases), and cases with separate populations of lymphoblasts and myeloblasts (one case). Using the immunologic panel and derived criteria to subtype AML, correspondence of the immunophenotype to the FAB subtypes M1, M2, M4, and M5 was possible in greater than 80% of cases. A combined classification of the immunophenotype and FAB morphology/cytochemistry was devised for AML subtyping. It is recommended that immunophenotyping should be done at least in all cases with negative or inconclusive cytochemistry. At present, we suggest that until a “gold standard” for identifying leukemic subtypes is developed, the best method for typing acute leukemia is by using a combination of morphology, cytochemistry and immunophenotyping.

MATERIAL AND METHODS

Morphologic, Cytochemical and Immunological Studies

The peripheral blood and bone marrows of 138 patients (122 adults, 16 children) with acute leukemia (AL) diagnosed over 2½ years, between December 1983 and June 1986, were tested for surface membrane, cytoplasmic, and nuclear antigens and were classified by the FAB Cooperative Group classification using Wright-stained smears and cytochemical stains. Cases of chronic myelogenous leukemia (CML) in blast crisis were not included in this study. The cytochemical stains used included periodic acid Schiff (PAS), SBB, MPO, nonspecific esterase-butyrate (NSE), and in some cases chloroacetate esterase (CAE) and acid phosphatase (AP). According to the number of cells available, testing was done with the monoclonal antibodies and heteroantisera shown in Table 1 by using immunofluorescence microscopy. The monoclonal antibodies were selected for testing on the basis of previously reported type specificity.2-8-11,18,27-34 Some antibodies (AML223, PMN6, PMN29, FMC10, Leu M3, PIM1, and PLT1) were added as they became available.

FAB Classification

The FAB Cooperative Group classification12-15 with minor modification was used on the peripheral blood and bone marrow smears. The myeloid leukemias were subclassified according to the following criteria:

M1: Predominance of myeloblasts with <10% granulocytic differentiation.

From the Leukemia Management Group, Hamilton Regional Hospitals and McMaster University, Hamilton, Ontario, Canada. Submitted March 3, 1986; accepted July 5, 1986.

P.B.N. is supported by the Hamilton Civic Hospitals Research Fund.

Address correspondence to Dr Peter B. Neame, 189 Wilson Way, Lyne Paddock, Kidlington, Oxon, England

Address reprint requests to Dr Peter B. Neame, Department of Hematology, Hamilton General Hospital, Barton Street East, Hamilton, Ontario, Canada, L8L 2X2.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1986 by Grune & Stratton, Inc.

0006-4971/86/6806-0027$3.00/0

Blood. Vol 68, No 6 (December), 1986: pp 1355-1362

1355
Table 1. Antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Cluster Designation</th>
<th>Molecular Weight</th>
<th>Specificity</th>
<th>Source</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu 1</td>
<td></td>
<td>5 67</td>
<td>T lineage</td>
<td>Becton Dickinson</td>
<td>27</td>
</tr>
<tr>
<td>T, T4, T6, T8, T11</td>
<td>3, 4, 1, 8, 2</td>
<td>19-29, 55, 45/12, 32, 50</td>
<td>T lineage</td>
<td>Coulter Immunology</td>
<td>28</td>
</tr>
<tr>
<td>OKT9</td>
<td>NA</td>
<td>90</td>
<td>T lineage</td>
<td>Orthodiagnostic</td>
<td>28</td>
</tr>
<tr>
<td>B1, B2, B4</td>
<td>20, 21, 19</td>
<td>35, 140, 95</td>
<td>B lineage</td>
<td>Coulter Immunology</td>
<td>12</td>
</tr>
<tr>
<td>BA1, BA2</td>
<td>24, 9</td>
<td>45/65/65, 24</td>
<td>B lineage</td>
<td>Hybritech</td>
<td>29</td>
</tr>
<tr>
<td>J5</td>
<td>10</td>
<td>100</td>
<td>Calla</td>
<td>Coulter Immunology</td>
<td>7, 12</td>
</tr>
<tr>
<td>HLA-DR (la)</td>
<td>NA</td>
<td>29-34</td>
<td>B lineage, monocytic, myeloblast</td>
<td>Becton Dickinson</td>
<td>30</td>
</tr>
<tr>
<td>Leu M1</td>
<td>NA</td>
<td>NA (x-hapten)</td>
<td>Granulocytic, monocytic</td>
<td>Becton Dickinson</td>
<td>31</td>
</tr>
<tr>
<td>My7, My9, Mol</td>
<td>w13, NA, 11</td>
<td>160, 68-74, 155/94</td>
<td>Granulocytic, monocytic</td>
<td>Coulter Immunology</td>
<td>10, 32, 37</td>
</tr>
<tr>
<td>My4, Mo2</td>
<td>w14, w14</td>
<td>55, 55</td>
<td>Monocytic</td>
<td>Coulter Immunology</td>
<td>10, 33</td>
</tr>
<tr>
<td>AML 2.23</td>
<td>NA</td>
<td>NA</td>
<td>Monocytic</td>
<td>Hybritech</td>
<td>9</td>
</tr>
<tr>
<td>D5D6(CAML 1)</td>
<td>NA</td>
<td>NA</td>
<td>Granulocytic, monocytic</td>
<td>UCLA Tissue Typing Lab</td>
<td>18</td>
</tr>
<tr>
<td>PMN 6, PMN 29</td>
<td>NA, NA, NA</td>
<td>NA, NA, NA</td>
<td>Granulocytic</td>
<td>Hybritech</td>
<td>9</td>
</tr>
<tr>
<td>FMC 10</td>
<td>15</td>
<td>NA</td>
<td>Granulocytic</td>
<td>AMD-Cedarlane</td>
<td>34</td>
</tr>
<tr>
<td>PLT1</td>
<td>NA</td>
<td>NA</td>
<td>Megakaryocytic</td>
<td>Coulter Immunology</td>
<td>37</td>
</tr>
<tr>
<td>FVIIIIR</td>
<td>NA</td>
<td>NA</td>
<td>Megakaryocytic</td>
<td>Cappel</td>
<td>36, 38</td>
</tr>
<tr>
<td>EMcAb*</td>
<td>NA</td>
<td>NA</td>
<td>Erythroid/Lymphoid</td>
<td>B.S. Clarke</td>
<td>39</td>
</tr>
<tr>
<td>TdT†</td>
<td>NA</td>
<td>NA</td>
<td>Lymphoid</td>
<td>Pharmacia</td>
<td>39</td>
</tr>
<tr>
<td>Immunoglobulin†, μ chain, kappa and lambda light chain</td>
<td>NA</td>
<td>NA</td>
<td>B lineage</td>
<td>Tago</td>
<td>40, 41</td>
</tr>
</tbody>
</table>

*Erythroid monoclonal antibody—not commercially available.
†Polyclonal.
NA, Not available.

M2: More than 30% myeloblasts with >10% differentiating granulocytes, NSE <20%.
M3: (a) Hypergranular promyelocytes with numerous Auer rods on Wright-stain or CAE. (b) A variant form showing cells with bilobed, multilobed or reniform nuclei (NSE-negative) and relative scarcity of hypergranular promyelocytes or of primitive cells with multiple Auer rods.
M4: Monocytic cells with >20% but <80% NSE-butyrate positivity.
M5: Monocytic cells with >80% NSE positivity. (a) Monoblastic, poorly differentiated. (b) Monocytic, differentiated.
M6: More than 50% erythroblasts with >30% myeloblasts excluding the erythroid cells.

The criteria used for the myeloid subclassification were similar to the revised FAB classification recently published and were introduced in our laboratory in 1983 as a result of the FAB reports in 1981 and 1982 from examination of our data.

Cell Preparation and Immunofluorescence

Monoclonal antibodies. This has been described in detail in a previous paper. In brief: after Ficoll-Hypaque gradient separation, cells were incubated for 30 minutes with the monoclonal antibody (McAb). After three washes the cells were then incubated for 30 minutes with fluorescein-conjugated antimmunoglobulin. To increase the reactivity of some monoclonal antibodies (My9, My7, My4, Leu M1, PMN 6/29, and B4) biotin-conjugated antimmunoglobulin was used as the second antibody and for the third stage fluorescein conjugated avidin was added. After three further washes, cytospin preparations were made and examined under the fluorescent microscope.

Heteroantisera

Surface immunoglobulin. Cells were incubated with fluorescein-conjugated antihuman immunoglobulin for 30 minutes. After three washes, cytospin preparations were made and examined using a fluorescent microscope.

Cytoplasmic immunoglobulin. After fixing for five minutes in acetone, cytospin preparations of cells were incubated for 30 minutes with fluorescein-conjugated antihuman immunoglobulin. After three washes, the preparations were examined using a fluorescent microscope.

Terminal deoxynucleotidyl transferase. An indirect immunofluorescent assay using rabbit anti-terminal deoxynucleotidyl transferase (anti-TdT) was performed as previously described.

Criterion for all methods. Cases where more than 25% of mononuclear cells were reactive with antibody were considered positive.

Comparison of the Derived Immunophenotype with the FAB Classification

Two experienced observers independently classified (using the FAB classification as described above), randomly ordered, and...
IMMUNOPHENOTYPING ACUTE LEUKEMIA

The reagents used to type acute leukemia are shown in Table 1. Some reagents showed a lack of specificity, poor reactivity, an irregular response to differentiation, or maturation or infrequent positivity in AML and were dropped from our panel. The reagents ultimately used to immunophenotype are shown in Tables 2, 3 and 4.

**RESULTS**

**Comparison of the FAB Classification by the Two Observers**

Of the 138 cases, there was agreement in the FAB diagnosis of 83% of the cases (113 cases). In the remaining 17% (23 cases), 15 cases showed FAB subtype differences (M1/M2 [4], M1/M5 [1], M2/M4 [2], M4/M5 [2] or L1/L2 [6]) while eight cases were unclassifiable (AUL). In 30 cases (22%), there was negative cytochemical staining. The two observers were concordant in their FAB diagnosis in 20 of these cases. Of the remaining 10 cases, eight were undifferentiated and two were minor subtype differences.

**Initial Selection of Antibodies**

The reagents used to type acute leukemia are shown in Table 1. Some reagents showed a lack of specificity, poor reactivity, an irregular response to differentiation, or maturation or infrequent positivity in AML and were dropped from our panel. The reagents ultimately used to immunophenotype are shown in Tables 2, 3 and 4.

**Relationship Between Immunophenotype and FAB Classification in AML**

The reactivity pattern of 75 cases of AML with monoclonal antibodies against myeloid differentiation antigens is shown in Table 2. It will be noted that 87% of the cases were identified by My9 and 75% by My7. Of these 75 cases, 12 were My7+ and My9+; five My7+ and My9++; and three My7- and My9+. The remaining 55 cases (73%) were positive for both antibodies (My7+, My9+). Ninety-six percent of the cases of AML expressed either My9, My7, or both. Three of the 75 cases that failed to be identified by My7 and My9 were later recognized by other criteria to be myeloid in origin. In two of the patients, the bone marrows were considered to be M5 by morphology and NSE reaction (>80%) and were both My4-positive. A further case, SBB- and MPO-positive, was negative with all myeloid antibodies used (My7+, My9+, My4+, and Leu M1-).

From surveying our initial results we recognized that both My7 and My9 antibodies would be useful as an initial screen for acute myeloid leukemia. Pooling My7 and My9 antibodies was first undertaken when insufficient cells had been obtained by marrow aspirate or on peripheral blood. In 20 further cases pooled My7/My9 antibodies were compared with the results when the reagents were used individually. Using the pooled reagents, an increase in the intensity of the reaction, and sometimes in the number of positive cells, was observed in the majority of cases. In a similar manner, we now pool Leu 1 and TdT (see Table 4).

Table 2 shows that the immunophenotyping can distinguish between FAB M1 and M2. None of the 18 cases classified as FAB M1 by morphological examination were Leu M1-positive, whereas FAB M2 were positive in 15 of 17 cases (88%).

The reactivity of the reagent AML 2.23 has not previously been reported in acute promyelocytic leukemia (FAB M3).
We found that all four cases of FAB M3 including a variant form gave a positive reaction with AML 2.23. All of these cases were My4- but the variant form was Ia+ in contrast to the hypergranular form which was Ia- . The combination of Ia-, AML 2.23+, and My4- was not observed in FAB M1, M2, M4, or M5.

As previously reported, My4 reacted positively in the majority (90%) of cases of FAB M4 and M5. It gave a positive reaction in only two of 42 cases (5%) classified as nonmonocytic by the FAB classification and a negative NSE reaction. In seven cases NSE-butyrate and My4 reactivity were not concordant.

Eighty-six cases which typed as AML were tested with anti-TdT and two cases were positive. One of the cases was further cases (AML). Two cases were positive. One of the cases was diagnosed as M1, M2, M4, or M5. As previously reported, My4 reacted positively in the majority (90%) of cases of FAB M4 and M5. It gave a positive reaction in only two of 42 cases (5%) classified as nonmonocytic by the FAB classification and a negative NSE reaction. In seven cases NSE-butyrate and My4 reactivity were not concordant.

By observing certain patterns using monoclonal antibodies against myeloid differentiation antigens, a myeloid immunophenotype corresponding to the FAB myeloid subclassification was recognized for M1, M2, M4, and M5 (Table 5). Figure 1 shows that by the immunophenotypic criteria, 85% of cases diagnosed as M1, 93% as M2, 81% as M4 and 100% as M5 corresponded to their appropriate FAB morphologic diagnosis. The hypergranular FAB M3 appeared to be Ia-, AML 2.23+, and My4-, but our numbers are too small to draw a firm conclusion. Criteria for the diagnosis of M63 and M735,36 have been published in the literature.

Relationship Between Immunophenotype and FAB Classification in ALL

As previously demonstrated, there was a lack of correlation between the FAB L1, L2 classification and the ALL immunophenotype. Furthermore, one case classified as FAB L3 showed no Slg positivity and typed as cALL (B4+, J5+, Cμ+, Slg-). Our immunophenotypic results with acute lymphoid leukemia correspond to those reported in the literature. The reactivity pattern with monoclonal antibodies of 51 patients classified as ALL are shown in Table 3. B4 was specific for non-T lineage ALL being positive in all patients tested, and negative in 13 cases of T-ALL. Anti-TdT was positive in all except six cases of B-ALL showing positive Slg. Because BA2 was positive in four out of nine cases of AML and two out of three cases of T-ALL, and because BA1 was considered less reliable than B4 for subtyping Null ALL, both antibodies were dropped from our panel. Twelve cases (24%) diagnosed as ALL by the FAB classification showed lymphoid markers and a myeloid marker on immunophenotyping.

Cases With Disagreement Between the Morphological Diagnosis and the Immunophenotype

Table 6 shows the results of 14 cases where there was disagreement between the morphologic diagnosis and the immunophenotype. Thirteen of the cases were undifferentiated by cytochemical staining. Eight of the cases were originally unclassifiable (AUL, M1, or L2) by morphology.

Table 4. Monoclonal Antibodies for Classifying Acute Leukemia

<table>
<thead>
<tr>
<th>First Line</th>
<th>My7/9</th>
</tr>
</thead>
<tbody>
<tr>
<td>2nd Line‡</td>
<td>Leu M1, My4, EMcAb, J5, LA, PMN 6/29, AML 2.23</td>
</tr>
<tr>
<td>3rd Line‡</td>
<td>FVIIIR, PLT1, Gp IIB/Illa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute Myeloid Leukemia</th>
<th>Acute Lymphoid Leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>TdT*</td>
<td>B4</td>
</tr>
<tr>
<td>α</td>
<td>J5, Cµ, Slg*</td>
</tr>
<tr>
<td>T3, T6, T9</td>
<td></td>
</tr>
<tr>
<td>Kappa* Lambda*</td>
<td>T4, T8</td>
</tr>
<tr>
<td>B1, B2</td>
<td></td>
</tr>
</tbody>
</table>

*Heteroantiserum.
†An addition would be Leu 9, (CD7, 40 kd).‡Second and third line subsequently performed according to lineage established by the first line.
§EMcAb, erythroid monoclonal antibody; not commercially available.

Table 5. Myeloid Immunophenotypic Subclassification

<table>
<thead>
<tr>
<th>Myeloid Immunophenotypic Subclassification</th>
<th>M1</th>
<th>M2</th>
<th>M4</th>
<th>M5</th>
</tr>
</thead>
<tbody>
<tr>
<td>My7/9-positive, Leu M1- and My4-negative</td>
<td>17</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>My7/9-positive, Leu M1-positive, My4-negative</td>
<td>2</td>
<td>14</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ia-negative, AML 2.23-positive, My4-negative</td>
<td>1</td>
<td>1</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>My4-positive but less than 45%</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>Grey zone My4 (between 45-55%) and PMN 6/29-positive</td>
<td>20</td>
<td>15</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td>My4-positive greater than 55%</td>
<td>85%</td>
<td>93%</td>
<td>81%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 6. Myeloid Immunophenotypic Subclassification and the FAB-Cytocatalytic Classification

<table>
<thead>
<tr>
<th>Immunophenotype</th>
<th>M1</th>
<th>M2</th>
<th>M4</th>
<th>M5</th>
</tr>
</thead>
<tbody>
<tr>
<td>M1</td>
<td>17</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>M2</td>
<td>2</td>
<td>14</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>M4</td>
<td>1</td>
<td>1</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>M5</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>13</td>
</tr>
</tbody>
</table>

Fig 1. Comparison of results of the immunophenotypic myeloid subclassification and the FAB-cytocatalytic classification.
IMMUNOPHENOTYPING ACUTE LEUKEMIA

Table 6. Laboratory Data of 14 Patients with Disagreement Between FAB Diagnosis and Immunophenotype

<table>
<thead>
<tr>
<th>No.</th>
<th>FAB</th>
<th>Cytochemistry</th>
<th>Positive Immunologic Markers</th>
<th>Immunophenotype</th>
<th>Final Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M1</td>
<td>Myeloid</td>
<td>Undifferentiated</td>
<td>UD*</td>
<td>AML</td>
</tr>
<tr>
<td>2</td>
<td>M1</td>
<td>UD</td>
<td>TdT, B4, J5</td>
<td>Common ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>3</td>
<td>AUL †</td>
<td>UD</td>
<td>TdT, B4, J5, B1, BA2</td>
<td>Common ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>4</td>
<td>AUL</td>
<td>UD</td>
<td>TdT, B4, BA2, My7</td>
<td>Null ALL (plus My7)</td>
<td>ALL</td>
</tr>
<tr>
<td>5</td>
<td>L2</td>
<td>UD</td>
<td>My9, My7, My4</td>
<td>AML-M4</td>
<td>AML</td>
</tr>
<tr>
<td>6</td>
<td>M1</td>
<td>UD</td>
<td>B4, B1, B2, SlgA, Lambda</td>
<td>B ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>7</td>
<td>M1</td>
<td>UD</td>
<td>TdT(36%), B4(20%), Leu M1,</td>
<td>M x L ‡</td>
<td>M x L</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>My9, My7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Double labeling showed separate populations of lymphoid and myeloid cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M2</td>
<td>UD</td>
<td>TdT, B4, J5, My7</td>
<td>Common ALL (plus My7)</td>
<td>ALL</td>
</tr>
<tr>
<td>9</td>
<td>AUL</td>
<td>UD</td>
<td>TdT, BA1, BA2</td>
<td>Null ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>10</td>
<td>AUL</td>
<td>UD</td>
<td>My7, B4, (TdT Neg, Ia Neg)</td>
<td>AML (plus B4)</td>
<td>AML</td>
</tr>
<tr>
<td>11</td>
<td>AUL</td>
<td>UD</td>
<td>TdT, B4, J5, Ia</td>
<td>Common ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>12</td>
<td>AUL</td>
<td>UD</td>
<td>TdT, B4, J5, Ia</td>
<td>Common ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>13</td>
<td>AUL</td>
<td>UD</td>
<td>TdT, B4, J5, Ia</td>
<td>Common ALL</td>
<td>ALL</td>
</tr>
<tr>
<td>14</td>
<td>AUL</td>
<td>UD</td>
<td>My7/My9</td>
<td>AML (M1)</td>
<td>AML</td>
</tr>
</tbody>
</table>

*UD, undifferentiated. †AUL, acute undifferentiated leukemia (M1/L2). ‡M x L, dual population of myeloblasts and lymphoblasts.

In the remaining six cases there had been FAB concordance but the result was in disagreement with the immunophenotype. One of these cases showed negative reactivity with all monoclonal antibodies used despite FAB M1 morphology and strong positivity with MPO and SBB. The immunophenotype included three cases with a mixed lineage phenotype and a single case with a dual population of lymphoblasts and myeloblasts (biclonal, biphenotypic). The final diagnosis for therapeutic purposes of the cases with a mixed lineage phenotype was considered as either ALL or AML according to the predominant lineage observed on combined morphologic, cytochemical, and immunologic assessment.

**DISCUSSION**

The FAB classification provides a common language for comparing and treating acute leukemia; however, difficulties with some of the diagnostic criteria are evident. The major difficulties include distinguishing M1 from L2 in cases where cytochemical staining is negative and M1 from M2 though their distinction has been improved in the recent revised FAB classification.

From our initial investigation, a panel of commercially available antibodies to discriminate and subtype acute leukemia was devised and is used in the Hamilton region (Table 4). Since its initiation, the panel has been tested prospectively on 58 AL cases. It was developed to obtain the maximum of information using the smallest number of tests. In addition, the panel is performed in sequence so that the most useful information is likely to be derived from specimens which contain an insufficient number of cells for complete analysis. The first line screen is used to distinguish acute myeloid from acute lymphoid leukemia and to separate B and T lineage ALL. It will also identify some cases of AMLL. The second panel discriminates a rare case not recognized by the first panel and further subtypes acute myeloid and lymphoid leukemia. Cases not defined by the first two panels are investigated by a third panel which includes antibodies that recognize megakaryocyte/platelet differentiation or further discriminate subtypes of ALL.

The immunophenotype will discriminate cases of acute lymphoid from myeloid leukemia which remain undifferentiated by cytochemistry (22% of cases) and thereby clarifies the majority of the disagreements (M1 v L2) noted between observers using the FAB classification. In addition, cases with a mixed lineage phenotype (13% of cases) and, less commonly, dual populations of lymphoid and myeloid cells (<1% of cases) can be identified. It seems the immunophenotype should be regarded as a reliable method of classifying acute leukemia. Monoclonal antibodies with the same cluster differentiation (CD) number as defined by the First and Second Leukocyte Antigen Workshop could possibly be used to replace some of the monoclonal antibodies utilized in our panel; however, despite their having the same CD number, we found differences in the reactivity of My4 and MO2.

The subclassification of acute lymphoblastic leukemia by immunophenotyping is well-documented. To date all our cases of non-T-ALL have shown B4 reactivity. Null ALL was identified in the panel by reactivity with anti-TdT and B4 only, but Anderson et al. have observed presumed cases of non-T ALL that were TdT and B4-. As previously reported the ALL immunophenotype did not correspond with the FAB classification.

In most previous reports using different antibodies there has been little correlation between the FAB myeloid subtypes and antigenic phenotype in AML. However, the expression of certain antigens have correlated with the FAB classification. Using our immunologic panel and derived criteria to subtype AML, correspondence of the immunophenotype to the FAB subtypes M1, M2, M4, and M5 was...
possible in over 80% of cases (Fig 1). Using the immunophenotype together with the FAB morphology and cytochemistry (Table 7) it is possible to obtain almost perfect concordance between observers.25 It should be emphasized that this scheme is based on the testing of a relatively small sample (75 AML cases). Combining FAB M1, M2, and M4 as so-called M7 is unnecessary when using the combined FAB/immunophenotypic classification as the various myeloid subtypes can be distinguished.

Should all cases of acute leukemia be immunophenotyped? A major difficulty of the FAB classification is encountered in cases with negative cytochemical staining. This was found in 30 of our 138 cases (22%). Though our two observers were concordant in 20 of these 30 cases, in five of the discordant observations there was disagreement between the concordant FAB classification and the immunophenotype. Of the remaining ten cases, eight were undifferentiated (M1 or L2). Immunophenotyping may therefore be useful in the cases with negative cytochemistry. Clarifying the diagnosis in this group of patients will allow therapy to be given according to the type of leukemia diagnosed. A controlled study will be required to ascertain whether this results in an improved therapeutic outcome. Acute mixed lineage leukemia is found in 13% of our cases and could rarely be recognized without immunophenotyping. If therapeutic outcome with standard therapy is found to be inferior to outcome in single lineage leukemia in future studies (in progress), an argument could be made for applying immunophenotyping to all cases of AL.

At this time, the immunophenotype cannot be regarded as the “gold standard” for classifying all cases of acute leukemia. Unfortunately, there is no “gold standard.” To date, the most widely accepted classification system has been the FAB classification and for this reason the design of this study was to compare the immunophenotyping of acute leukemia with the FAB classification. The purpose of our paper is to provide data which may improve current systems.17 The process will hopefully help to establish a classification with biologic meaning or prognostic relevance; however, further controlled studies will have to be done to determine whether therapeutic decisions based upon immunophenotyping in adults improve the outcome as is possible in ALL in childhood.62,63 Such studies cannot be done until the classification is firmly established.

The possibility that the antigenic phenotyping of AML with monoclonal antibodies may identify groups which are of prognostic importance has been recently reported.60,61 A correlation with My1 reactivity and successful remission induction has been suggested.60 In addition, Griffin has noted a correlation of My7 reactivity with poor prognosis in AML, an observation noted previously with My4.61 The FAB classification has only been minimally successful in identifying groups of clinical relevance.60

Following the recent introduction of probes to test for rearrangement of the immunoglobulin or T cell antigen receptor genes,64-69 it seemed that a test would be available to distinguish acute lymphoid from myeloid leukemia with certainty; however, recently immunoglobulin and T cell antigen receptor rearrangement have been noted in cases with the AML phenotype.66,70 Thus in cases with a somatic rearrangement of the immunoglobulin or T cell antigen receptor gene, acute lymphoid leukemia may be suspected but is not proven. Cases with a germ-line configuration on DNA analysis would suggest nonlymphoid leukemia.64 The addition of karyotyping to the morphological and immunologic assessment should also contribute to the detailed cellular phenotype in acute leukemia.64,67

ACKNOWLEDGMENT

We wish to thank Dr Bryan Clarke of McMaster University for supplying his monoclonal antibody and the Hematology technologists at the Hamilton General Hospital for performing the tests.

REFERENCES

5. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton
IMMUNOPHENOTYPING ACUTE LEUKEMIA


44. Mirro J, Antoun GR, Zipf TF, Melvin S, Stass S: The E...
rosette-associated antigen of T cells can be identified on blasts from patients with acute lymphoblastic leukemia. Blood 65:363, 1985
54. Blazar BR, Brunning RD, Bloomfield CD, McKenna RW, Robison LL, LeBlanc TW, Gajl-Peczalska K, Nesbit ME, Kersey IH: Correlation of monoclonal antibody (MoAb) phenotypes with FAB morphology in acute nonlymphocytic leukemia (ANLL). Blood 60:120a, 1982 (Suppl. 1) (abstr)
Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML

PB Neame, P Soamboonsrup, GP Browman, RM Meyer, A Benger, WE Wilson, IR Walker, N Saeed and JA McBride